Evaluation of the use of low-molecular-weight heparin for venous thromboembolism prophylaxis in medical patients

被引:1
|
作者
du Plessis, J. A. [1 ]
van Blydenstein, S. A. [2 ,3 ]
Wong, M. [2 ,3 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Johannesburg, South Africa
[2] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Dept Internal Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
来源
SAMJ SOUTH AFRICAN MEDICAL JOURNAL | 2020年 / 110卷 / 03期
关键词
UNFRACTIONATED HEPARIN; COST-EFFECTIVENESS; RISK; PREVENTION; THROMBOSIS; DRUG; VTE;
D O I
10.7196/SAMJ.2020.v110i3.14279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Venous thromboembolism (VTE) complicates a significant proportion of medical admissions. As well as increasing patient morbidity, pulmonary embolism is one of the commonest preventable causes of in-hospital death. An increase in the use of pharmacological preventive measures has been advocated in recent years. South African (SA) and international guidelines have been published in an effort to promote the safe use of VTE prophylaxis. Objectives. To describe adherence to both local and international recommendations for VTE prophylaxis in an SA hospital with regard to appropriateness of the decision to prescribe or withhold low-molecular-weight heparin (LMWH), and to observe the practice of dose adjustment in special population groups. Methods. This was a prospective, observational study, and data were collected from consenting adults admitted to the medical wards. We assessed the patients' VTE risk, bleeding risk and the presence of contraindications at the time of LMWH prescription as well as the dose prescribed, specifically taking into consideration adjustment for renal dysfunction and obesity. Results. Three hundred and fifty-two patients were enrolled, of whom 51.4% were male and 58.5% received LMWH. Primary outcomes. The appropriate overall decision according to both SA and international guidelines was made in 254 cases (72.2%). The inappropriate decision according to both guidelines was made in 79 cases (22.4%) and the appropriate decision according to one guideline only was made in 18 cases (5.1%), while 1 case (0.3%) was not categorised. Contraindications to VTE prophylaxis were present in 35 patients (9.9%), but 9 of these patients nevertheless received LMWH. An incorrect dose was prescribed in 36 cases (17.5%), the most common reason being an inappropriate reduction in the dose in mild renal dysfunction. Secondary outcomes. Other medications that may have increased bleeding risk were prescribed in 46 patients who received LMWH (22.3%). Mechanical prophylaxis was indicated in 25 (7.1%) of the total sample; however, none received this. Conclusions. Overall adherence to published guidelines for VTE prophylaxis has improved compared with other published reviews on the topic, but documentation of patients' VTE risk in files is poor. Overuse in low-risk patients may be an unintended consequence of the widespread advocacy of LMWH use in hospital, highlighting the importance of adequate VTE risk stratification. Incorrect dosing in special population groups is an issue that needs to be addressed, as is non-utilisation of mechanical prophylaxis methods.
引用
收藏
页码:235 / 242
页数:8
相关论文
共 50 条
  • [21] Low-molecular-weight heparin prescribing for venous thromboembolism in cancer patients
    Stewart, David
    Rikhye, Somi
    Odle, Brian
    Flores, Emily
    [J]. PHARMACOTHERAPY, 2013, 33 (05): : E51 - E51
  • [22] Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients-A Pharmacoeconomic Analysis
    Wilbur, Kerry
    Lynd, L. D.
    Sadatsafavi, M.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (05) : 454 - 465
  • [23] Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: An economic evaluation
    Huse, DM
    Cummins, G
    Taylor, DCA
    Russell, MW
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (01): : S10 - S16
  • [24] PROPHYLAXIS OF THROMBOEMBOLISM IN ORTHOPEDICS AND TRAUMATOLOGY BY LOW-MOLECULAR-WEIGHT HEPARIN
    BARSOTTI, J
    ROSSET, P
    PLANES, A
    MARCHAL, C
    ROBERT, C
    BERTRAND, P
    [J]. REVUE DE CHIRURGIE ORTHOPEDIQUE ET REPARATRICE DE L APPAREIL MOTEUR, 1992, 78 : 229 - 234
  • [25] PROPHYLAXIS OF THROMBOEMBOLISM WITH LOW-MOLECULAR-WEIGHT HEPARIN DURING PREGNANCY
    HARENBERG, J
    LEBER, G
    ZIMMERMANN, R
    SCHMIDT, W
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 1987, 47 (01) : 15 - 18
  • [26] Low-molecular-weight heparin for initial treatment of venous thromboembolism
    Brewer, D
    [J]. AMERICAN FAMILY PHYSICIAN, 2005, 72 (01) : 75 - 76
  • [27] Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly
    Pineo, GF
    Hull, RD
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2005, 11 (01) : 15 - 23
  • [28] Prescription of low molecular weight heparin (LMWH) for prophylaxis against venous thromboembolism (VTE) in medical patients
    Wardle, J
    Webb, J
    Holmes, J
    Myers, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 7 - 7
  • [29] Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma
    Gazal, Stav
    Lebel, Eyal
    Kalish, Yosef
    Makranz, Chen
    Gatt, Moshe E.
    Goldschmidt, Neta
    Nachmias, Boaz
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 52 - 57
  • [30] Lower Mortality and Morbidity with Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Spine Trauma
    Neifert, Sean N.
    Chapman, Emily K.
    Rothrock, Robert J.
    Gilligan, Jeffrey
    Yuk, Frank
    McNeill, Ian T.
    Rasouli, Jonathan J.
    Gal, Jonathan S.
    Caridi, John M.
    [J]. SPINE, 2020, 45 (23) : 1613 - 1618